Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.
Esophageal Cancer
DRUG: Endostar|RADIATION: Radiotherapy
Objective Response Rate (ORR), 1 month after treatment
Overall Survival (OS), 2 years|Time to Progression (TTP), every three months until disease progression|Clinical Benefit Rate (CBR), 1 month after treatment|Serum VEGF Levels, at baseline and 6 weeks|Incidence of Adverse Events, up to 3 months
This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.